ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2203

DEK’s Autoantigenicity In Juvenile Idiopathic Arthritis Resides In Its C-Terminal 25 Amino Acids

Barbara S. Adams1, Miguel Rivas1, Yuanfan Ye1, Lili Zhao2, Maureen Legendre3 and Nirit Mor-Vaknin3, 1University of Michigan, Ann Arbor, MI, 2Department of Statistic, University of Michigan, Ann Arbor, MI, 3Internal Medicine, University of Michigan, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoantibodies and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: The nuclear oncoprotein DEK is a known autoantigen associated with juvenile idiopathic arthritis (JIA) and other autoimmune diseases.  DEK is actively secreted by human macrophages and is a chemoattractant for neutrophils and T cells. We have previously demonstrated that DEK and DEK autoantibodies are abundant in inflamed synovia of JIA patients. Posttranslational modification, especially acetylation, increases DEK’s antigenicity substantially.  In agreement with previous observations by Szer et al., our studies of the nature of DEK autoantibodies have shown that autoantibodies from JIA patients recognize the DEK C-terminal region.  By screening 69 serum samples, including those from 38 patients with JIA, 20 patients with other inflammatory conditions, and 11 samples from healthy controls, we show that the C-terminal 25 amino acids (aa) alone is the most essential site for DEK antigenicity.

Methods: Sera were collected from patients being treated for JIA and other rheumatologic diseases in the Pediatric Rheumatology Division at the University of Michigan.  Samples were analyzed by a specific ELISA developed in our laboratory for the detection of DEK antibodies. Recombinant DEK His-tagged proteins, including full length(1-375aa), and partial length (187-375aa and 1-350aa) proteins were made in a baculovirus system, and were used as the antigen for ELISA and immunoblotting.   In addition, we inserted DEK’s C-terminal 25aa domain into a GST vector to be expressed by E. coli with subsequent purification.  ELISA results were calculated as area under the curve (AUC) by Simpson Rule.

Results: ELISA results showed significantly higher levels of DEK autoantibodies in sera of JIA patients compared to patients without JIA (p=0.01) or healthy controls (p=0.001).  Immunoblot screening against full length DEK (1-375aa), the DEK C-terminus 25aa (position 350-375), and full-length DEK minus the last 25 amino acids (1-350aa) confirms that DEK’s most immunogenic portion consists of the C-terminal 25aa. These results were also corroborated by expression of DEK’s C-terminal 25aa alone.

Conclusion: We have previously demonstrated presence of DEK and DEK autoantibodies in joints of JIA patients, resulting in development of immune complexes that contribute to joint inflammation. In addition, DEK plays an active role in recruiting neutrophils to joints, as well as in formation of neutrophil extracellular traps (NETs).  Our current data suggests that the C-terminal 25aa is the most immunogenic portion of DEK. This finding has significant importance with respect to future development of specific diagnostic tools for JIA, as well as for new strategies to eliminate DEK autoantibodies.


Disclosure:

B. S. Adams,
None;

M. Rivas,
None;

Y. Ye,
None;

L. Zhao,
None;

M. Legendre,
None;

N. Mor-Vaknin,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deks-autoantigenicity-in-juvenile-idiopathic-arthritis-resides-in-its-c-terminal-25-amino-acids/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology